mTORCI-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs

Science

Volumn 328, Issue 5982, 2010, Pages 1172-1176

  Dowling, Ryan J O ^a,d   Topisirovic, Ivan ^a   Alain, Tommy ^a   Bidinosti, Michael ^a   Fonseca, Bruno D ^a   Petroulakis, Emmanuel ^a   Wang, Xiaoshan ^a   Larsson, Ola ^a   Selvaraj, Anand ^b   Liu, Yi ^c   Kozma, Sara C ^b   Thomas, George ^b   Sonenberg, Nahum ^a  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c Intellikine Inc   (United States)

^d PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INITIATION FACTOR 4E BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MESSENGER RNA; CARRIER PROTEIN; EIF4EBP1 PROTEIN, MOUSE; EIF4EBP2 PROTEIN, MOUSE; INITIATION FACTOR; MTORC1 PROTEIN, HUMAN; MTORC1 PROTEIN, MOUSE; PHOSPHOPROTEIN; RAPAMYCIN; S6 KINASE; TRANSCRIPTION FACTOR;

BACTERIUM; CANCER; CARDIOVASCULAR DISEASE; CYTOLOGY; DIABETES; EUKARYOTE; MAMMAL; OBESITY; PROTEIN; RNA;

ANIMAL CELL; ARTICLE; CELL CYCLE PROGRESSION; CELL GROWTH; CELL PROLIFERATION; CELL SIZE; MAMMAL CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; ANIMAL; CELL CYCLE; CELL ENLARGEMENT; CELL LINE; CELL SURVIVAL; GENETICS; HUMAN; METABOLISM; MOUSE; MOUSE MUTANT; PHOSPHORYLATION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION;

EUKARYOTA; MAMMALIA;

ANIMALS; CARRIER PROTEINS; CELL CYCLE; CELL ENLARGEMENT; CELL LINE; CELL PROLIFERATION; CELL SIZE; CELL SURVIVAL; EUKARYOTIC INITIATION FACTORS; HUMANS; MICE; MICE, KNOCKOUT; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN BIOSYNTHESIS; RIBOSOMAL PROTEIN S6 KINASES; RNA, MESSENGER; SIGNAL TRANSDUCTION; SIROLIMUS; TRANSCRIPTION FACTORS;

EID: 77952967459     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1187532     Document Type: Article

References (27)

1. D. A. Guertin, D. M. Sabatini, Cancer Cell 12, 9 (2007).
2. N. Hay, N. Sonenberg, Genes Dev. 18, 1926 (2004).
3. A. Pause et al., Nature 371, 762 (1994).
4. A. Y. Choo, J. Blenis, Cell Cycle 8, 567 (2009).
5. K. Hara et al., Cell 110, 177 (2002).
6. S. H. Um, D. D'Alessio, G. Thomas, Cell Metab. 3, 393 (2006).
7. S. Wullschleger, R. Loewith, M. N. Hall, Cell 124, 471 (2006).
8. M. E. Feldman et al., PLoS Biol. 7, e38 (2009).
9. J. M. Garda-Martinez et al., Bioehem. J. 421, 29 (2009).
10. C. C. Thoreen et al., J. Biol. Chem. 284, 8023 (2009).
11. M. F. Favata et al., J. Biol. Chem. 273, 18623 (1998).
12. M. Ohanna et al., Nat. Cell Biol. 7, 286 (2005).
13. O. Le Bacquer et al., J. Clin. Invest. 117, 387 (2007).
14. A. De Benedetti, J. R. Graff, Oncogene 23, 3189 (2004).
15. J. R. Graff, B. W. Konicek, J. H. Carter, E. G. Marcusson, Cancer Res. 68, 631(2008).
16. A. C. Gingras et al., Genes Dev. 13, 1422 (1999).
17. L. Rong et al., RNA 14, 1318 (2008).
18. A. R. Tee, J. A. Tee, J. Blenis, FEBS Lett. 564, 58 (2004).
19. X. Wang, A. Beugnet, M. Murakami, S. Yamanaka, C. G. Proud, Mol. Cell. Biol. 25, 2558 (2005).
20. D. Ruggero, P. P. Pandolfi, Nat. Rev. Cancer 3, 179 (2003).
21. D. M. Sabatini, Nat. Rev. Cancer 6, 729 (2006).
22. E. Petroulakis et al., Cancer Cell 16, 439 (2009).
23. Y. Y. Kim et al., Cancer Res. 69, 8455 (2009).
24. M. Miron et al., Nat. Cell Biol. 3, 596 (2001).
25. J. Montagne et al., Science 285, 2126 (1999).
26. I. Conlon, M. Raff, J. Biol. 2, 7 (2003).
27. Rapamycin was from LC laboratories and Catbiochem, PP242 was from Intellikine, and Torin1 was from N. Gray and D. Sabatini. Experimental procedures are described in the supplementary material. We thank M. Pende for S6K1CA construct; M. Holcik and N. Colburn for antibody to PDCD4; K. Shokat, C. Rommel, L. W. Ler, S. Fumagalli, and M. Livingstone for advice; C. Lister and P. Kirk for assistance; and M. Daston for editing. Supported by a grant from the Canadian Cancer Society and a Howard Hughes Medical Institute international research scholarship (N.S.); a Terry Fox Foundation research studentship (R.J.O.D.); NIH Mouse Models for Human Cancer Consortium grant U01 CA84292-06 (N.S., G.T., and S.C.K.); a Leukemia and Lymphoma Society special fellowship (I.T.); Canadian Institutes of Health Research and Alberta Heritage Foundation for Medical Research postdoctoral fellowships (T.A.); a Natural Sciences and Engineering Research Council of Canada predoctoral fellowship (M.B.); a CIHR consortium training fellowship award (B.D.F.); the Research Participation Program at the Air Force Research Laboratory, Human Effectiveness Directorate, Bioscience and Protection, Wright-Patterson AFB, administered by the Oak Ridge Institute for Science and Education (A.S.); NIH grants R01 DK73802 and P50 NS057531 (G.T. and S.C.K.); and the John and Gladys Strauss Chair in Cancer Research (G.T.). G.T. is a paid consultant for Novartis Oncology. There are MTAs or patents restricting use of materials listed, described as: PP242 and Torin1.